Development Programs Indication Preclinical Phase 1 Phase 2 Phase 3 Status
VK2809 (TRβ Agonist) NASH
60%
Phase 2b VOYAGE trial ongoing
VK2735 (Dual GLP-1/GIP agonist) Metabolic disorders
35%
Phase 1 ongoing
VK0214 (TRβ Agonist) X-ALD
35%
Phase 1b ongoing
Other Programs Indication Preclinical Phase 1 Phase 2 Phase 3 Status
VK5211 (SARM) Hip fracture, muscle wasting
60%
Phase 2 completed
VK0612 (FBPase inhibitor) Type 2 Diabetes
60%
Phase 2a completed
VK1430 (DGAT-1 inhibitor) Hypertriglyceridemia, NASH
23%
Preclinical